Protalix Biotherapeutics Stock Today
| PLX Stock | USD 1.21 0.01 0.83% |
Performance0 of 100
| Odds Of DistressLess than 5
|
Protalix Biotherapeutics is trading at 1.21 as of the 25th of April 2024; that is 0.83 percent increase since the beginning of the trading day. The stock's open price was 1.2. Protalix Biotherapeutics has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Equity ratings for Protalix Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of May 1998 | Category Healthcare | Classification Health Care |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company has 73.05 M outstanding shares of which 6.46 M shares are at this time shorted by investors with about 15.22 days to cover. More on Protalix Biotherapeutics
Moving against Protalix Stock
| 0.8 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.77 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.75 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.63 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.6 | ELYM | Eliem Therapeutics | PairCorr |
| 0.56 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.41 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
Protalix Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Protalix Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Protalix Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Dror Bashan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Point Loma Resources Ltd, PHELIX N.V., Protalix Biotherapeutics Inc, Przetworstwo Tworzyw Sztucznych Plast-Box S.A., Pyrolyx AG] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, VN Index, VN All Shares, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Protalix Biotherapeutics report their recommendations after researching Protalix Biotherapeutics' financial statements, talking to executives and customers, or listening in on Protalix Biotherapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Protalix Biotherapeutics. The Protalix consensus assessment is calculated by taking the average forecast from all of the analysts covering Protalix Biotherapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Protalix Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Protalix Biotherapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Protalix Biotherapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protalix Biotherapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Protalix Biotherapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protalix Biotherapeutics' financial leverage. It provides some insight into what part of Protalix Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protalix Biotherapeutics (PLX) is traded on NYSE MKT Exchange in USA. It is located in Science Park, Karmiel, Israel, 2161401 and employs 208 people. Protalix Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 87.66 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Protalix Biotherapeutics's market, we take the total number of its shares issued and multiply it by Protalix Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Protalix Biotherapeutics runs under Biotechnology sector within Health Care industry. The entity has 73.05 M outstanding shares of which 6.46 M shares are at this time shorted by investors with about 15.22 days to cover.
Protalix Biotherapeutics has about 17.11 M in cash with (1.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Protalix Biotherapeutics Probability Of Bankruptcy
Ownership AllocationProtalix Biotherapeutics has a total of 73.05 Million outstanding shares. Protalix Biotherapeutics holds 9.76 pct. of its outstanding shares held by insiders and 13.899 pct. owned by third-party entities. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Protalix Ownership Details
Protalix Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Protalix Biotherapeutics jumping above the current price in 90 days from now is about 90.07%. The Protalix Biotherapeutics probability density function shows the probability of Protalix Biotherapeutics stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.7354 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Protalix Biotherapeutics will likely underperform. Additionally, protalix Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Protalix Biotherapeutics to move above the current price in 90 days from now is about 90.07 (This Protalix Biotherapeutics probability density function shows the probability of Protalix Stock to fall within a particular range of prices over 90 days) .
Protalix Biotherapeutics Historical Income Statement
Protalix Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Protalix's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Protalix Biotherapeutics revenue and expense. Protalix Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Protalix Biotherapeutics' Selling And Marketing Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 28.1 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024. View More FundamentalsProtalix Stock Against Markets
Picking the right benchmark for Protalix Biotherapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Protalix Biotherapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Protalix Biotherapeutics is critical whether you are bullish or bearish towards Protalix Biotherapeutics at a given time. Please also check how Protalix Biotherapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Protalix Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Protalix Biotherapeutics Corporate Directors
Protalix Biotherapeutics corporate directors refer to members of a Protalix Biotherapeutics board of directors. The board of directors generally takes responsibility for the Protalix Biotherapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Protalix Biotherapeutics' board members must vote for the resolution. The Protalix Biotherapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Roger Kornberg | Independent Director | Profile | |
| Amos BarShalev | Independent Director | Profile | |
| Aharon Schwartz | Independent Director | Profile | |
| David Granot | Independent Director | Profile |
How to buy Protalix Stock?
Before investing in Protalix Biotherapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Protalix Biotherapeutics. To buy Protalix Biotherapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Protalix Biotherapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Protalix Biotherapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Protalix Biotherapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Protalix Biotherapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Protalix Biotherapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
Already Invested in Protalix Biotherapeutics?
The danger of trading Protalix Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Protalix Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Protalix Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Protalix Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.